Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide — are now available in the Indian market. Here’s how they work, how ...

Remarkable new findings about the sugar stores in neurons have unlocked an entire new method of treating Alzheimer's disease ...

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

The Delhi High Court on Wednesday directed the Central Drugs Standard Control Organisation (CDSCO) to decide, within 3 month ...

Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting ...